Trials / Completed
CompletedNCT00330759
Study of Denosumab vs. Zoledronic Acid to Treat Bone Metastases in Subjects With Advanced Cancer or Multiple Myeloma.
A Randomized, Double-Blind, Multicenter Study of Denosumab Compared With Zoledronic Acid (Zometa) in the Treatment of Bone Metastases in Subjects With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple Myeloma.
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 1,779 (actual)
- Sponsor
- Amgen · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine if denosumab is non-inferior to zoledronic acid (Zometa®) in the treatment of bone metastases (lytic bone lesions from multiple myeloma) in subjects with advanced cancer and multiple myeloma (excluding breast and prostate cancer)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Denosumab | 120 milligrams by subcutaneous injection every 4 weeks |
| DRUG | Zoledronic Acid | 4 milligrams intravenous Zoledronic Acid over minimum 15 minutes every 4 weeks |
Timeline
- Start date
- 2006-06-01
- Primary completion
- 2009-04-01
- Completion
- 2011-10-01
- First posted
- 2006-05-29
- Last updated
- 2022-11-07
- Results posted
- 2014-04-09
Source: ClinicalTrials.gov record NCT00330759. Inclusion in this directory is not an endorsement.